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Abstract
Purpose of Review—Noroviruses are the most common cause of gastroenteritis outbreaks in 
long-term care facility (LTCFs). This review summarizes the most up-to-date knowledge on 
norovirus infection in LTCFs with the aim of identifying potential strategies for management.
Recent Findings—LTCF residents are at greater risk of norovirus infection. Early identification 
of norovirus infection and prompt initiation of appropriate supportive therapy are required to 
reduce morbidity and mortality. Measures to prevent outbreaks and reduce the risk of norovirus 
infection in LTCFs include timely diagnosis and implementation of infection control interventions 
to limit virus transmission.
Summary—Current guidelines for prevention and control are based on generic principles of 
infection control. Real-time reverse transcription-quantitative polymerase chain reaction assays 
have been the gold standard for the rapid and sensitive detection of noroviruses. With the recent 
breakthroughs of human norovirus in vitro culture, doors are now opened to evaluate the efficacy 
of environmental disinfectants and hand hygiene options. Additionally, development of licensed 
vaccines against noroviruses may provide another important tool for infection prevention among 
high-risk individuals.
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Introduction
Human noroviruses are globally important pathogens, contributing substantially to the 
burden of acute gastroenteritis across all age groups. The World Health Organization 
recently estimated that noroviruses caused 684 million illnesses and over 200,000 deaths 
globally in 2010 [1••]. Ahmed et al. conducted a systematic review of the scientific literature 
published from January 1,2008, to March 8,2014, and found that noroviruses were 
associated with almost one fifth of all cases of acute gastroenteritis, and the prevalence was 
higher in high income countries compared to low- and middle-income countries [2••].
Long-term care facilities (LTCFs) are common settings for outbreaks of norovirus infection, 
where they are responsible for 30–80% of acute gastroenteritis outbreaks [3, 4, 5, 6•]. While 
noroviruses can cause both sporadic infections and outbreaks in all age groups, older people 
are at higher risks of hospitalization and death [3], owing to intrinsic factors, such as age-
related immunosenescence or the presence of comorbid conditions, which result in more 
extended symptoms [7]. Additionally, elderly residents of LTCFs are at elevated risks of 
infection as a result of institutionalized confinement that promotes transmission by sharing 
rooms and touching common surfaces [8]. This review summarizes the most up-to-date 
knowledge on norovirus infection in LTCF residents with the aim of identifying potential 
strategies for management.
Infection in Older Adults and in LTCFs
Norovirus infection generally manifests as a relatively brief, self-limited illness in healthy 
immunocompetent individuals, although it can cause significant morbidity and mortality in 
frail elderly adults. Lindasay et al. reviewed 39 studies on risk estimates of norovirus 
infection and found a high burden of the infection in all ages with the highest rates of 
hospitalization and death among the elderly [3]. Older people are at higher risk of norovirus-
associated hospitalization, resulting in excess hospital stays and greater costs compared to 
young adults [3]. The overall estimates of disease burden suggest that noroviruses are 
responsible for approximately 10–20% of gastroenteritis hospitalizations, 10–15% of 
gastroenteritis deaths, and ≥0.2% of all-cause mortality among older adults in upper-middle-
income and high-income countries [9, 10, 11•, 12,13]. Additional data also suggest that 
noroviruses may trigger severe clinical complications, including acute renal failure, 
arrhythmia, chronic diarrhea, and severe enteropathy [14, 15].
Noroviruses are the most common cause of gastroenteritis outbreaks in LTCFs [16]. Review 
of US outbreak surveillance data show that over 60% of all norovirus outbreaks occur in 
LTCFs [17], while in other high-income countries norovirus outbreaks occur with roughly 
equal frequency in both acute-care hospitals and LTCFs. The definition of LTCFs differs 
between studies, but LTCFs generally refer to facilities that provide prolonged care for 
individuals who required daily living and/or nursing care support. Whereas most community 
cases of norovirus are self-limiting within 12–60 h, outbreaks of norovirus can significantly 
impact the institutionalized elderly and cause more severe or prolonged illness [18•, 19,20]. 
Several factors contribute to the enhanced risk of severe norovirus infection among older 
adults living in LTCFs, including nutritional status, immunodeficiency or senescence, 
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chronic inflammation, microbiome alterations, and the use of certain medications [21]. 
Decreased ability to maintain adequate personal hygiene may also increase individual risk 
among LTCF residents. Environmental factors, such as residence in close, shared quarters, 
use of shared facilities, and limited ability to isolate infected residents, may contribute to 
virus transmission in LTCFs. Shared dining facilities may also increase risk for foodborne 
exposures.
Infection Transmission
Transmission of human noroviruses can occur directly through person-to-person contact, or 
indirectly through consumption of contaminated food or water, or through contact with 
contaminated environmental surfaces (Fig. 1). Person-to-person transmission is responsible 
for >90% of the norovirus outbreaks in healthcare settings, where close living arrangements, 
shared facilities and contact with visitors and staff increase the risk of norovirus spread from 
one person to another [17, 22]. Foodborne transmission is another important route for the 
spread of noroviruses [1••] and can occur when food handlers contaminate food on site or 
during the earlier steps of food production [23]. An analysis of surveillance data on 
norovirus outbreaks in the USA, Europe, and New Zealand estimated that about 14% of 
norovirus outbreaks were attributed to foodborne transmission [24]. Noroviruses can also be 
transmitted through contaminated environment surfaces and aerosolized particles. 
Aerosolization of norovirus via vomitus can be particularly problematic in LTCFs, as virus 
particles can settle on surfaces and survive for long periods of time, leading to 
environmental contamination for future exposure [25].
The high shedding titers in feces and vomit [26], low level of infectious dose [27], and 
environmental stability [28] enable the virus to efficiently transmit via multiple modes. 
Transmission has also been reported to occur before the onset of symptoms [29], in the 
postsymptomatic period and during subclinical infections [30]. Investigations of norovirus 
outbreaks in LTCFs confirmed that infected persons can asymptomatically shed virus at high 
levels for at least 3 weeks [31••], although reports from nosocomial norovirus outbreaks 
have shown that symptomatic patients contribute primarily to transmission of infection [32].
Importance of Genetic Diversity and Evolution
Noroviruses, divided into at least six genogroups (GI-GVI) and more than 40 different 
genotypes (e.g., GII.4), are a genetically diverse group of non-enveloped single-stranded 
positive-sense RNA viruses [33]. The prevalence of infecting genogroups and genotypes 
differ between populations and route of transmission [22]. Genogroup I viruses are generally 
associated with foodborne or waterborne outbreaks [24, 34], while GII.4 viruses are strongly 
associated with person-to-person transmission and occur predominantly in healthcare and 
institutional settings [5, 6•, 35, 36]. Infections with GII.4 viruses are more likely to cause 
severe infections, leading to more hospitalization and deaths than those caused by other GII 
or GI viruses [37]. Multiple strains of noroviruses can cause human reinfection. Protective 
immunity to specific types of noroviruses has been reported, but with a limited duration 
[38].
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Despite the extensive genetic diversity, previous data suggest that GII.4 viruses are 
responsible for the majority of norovirus outbreaks worldwide [39], with a new GII.4 variant 
strain emerging every 2–4 years [40]. Several mechanisms may enhance GII.4 evolution, 
including the host herd immunity that drives antigenic drift in the hypervariable P2 domain 
[41••]. This domain of the viral capsid binds with human histo-blood group antigens 
(HBGAs), which serve as a point for initial viral attachment [42]. GII.4 viruses can bind a 
wider range of HBGAs than other genotypes, causing infections to a larger susceptible 
population [33]. Another explanation for the emergence of novel GII.4 variants is related to 
homologous recombination, which contributes to the emergence of the recent pandemic GII.
4 variants, such as GII.4 New Orleans 2009, and GII.4 Sydney 2012 [43]. The emergence of 
epidemic strains of noroviruses has contributed to the changing epidemiology of norovirus 
infection worldwide [44, 45].
Clinical Features and Diagnosis
Noroviruses are highly contagious. Ingestion of a small number of viral particles can lead to 
infection [27]. The onset of norovirus infection occurs after an average incubation period of 
1.2 (range 1–2) days [46]. Vomiting is a cardinal sign of norovirus infection, along with 
acute onset of other gastrointestinal symptoms including nausea, watery and non-bloody 
diarrhea, and abdominal cramps. Symptoms often last for 24– 72 h with complete recovery 
in immunocompetent individuals [19], although older frail people may present with 
prolonged symptoms and develop complications. One study describing the clinical 
characteristics of nosocomial outbreaks found that elderly hospitalized patients had 
prolonged symptoms with norovirus infection, and almost one third of the patients 
experienced dehydration [47]. Notably, the majority of those study participants (83.9%) had 
underlying chronic conditions, suggesting that the impact of norovirus infection is more 
pronounced among older adults with comorbid conditions.
It is difficult to diagnose norovirus gastroenteritis in individual patients on the basis of 
clinical features alone. The definition for norovirus infection in LTCFs requires the presence 
of both a compatible clinical presentation and a laboratory confirmation [48]. Historically, 
human noroviruses could not be cultured in vitro. However, Jones et al. recently published a 
protocol describing methods for culturing the GII.4-Sydney human norovirus strain directly 
in human B lymphocytes [49••]. This is a breakthrough research, as for the first time, a 
human norovirus can be grown in a culture dish. It enables research into the development of 
antiviral drugs, as well as opens a door to definitively evaluate the efficacy of infection 
control and prevention options.
Diagnostic methods of norovirus infection have focused on detecting viral RNA or antigen. 
In recent years, real-time reverse transcription-quantitative polymerase chain reaction (RT-
qPCR) assays have become the gold standard for the rapid and sensitive detection of 
noroviruses in stool, vomitus, foods, water, and environmental specimens [33]. However, 
virus detection by RT-qPCR does not always correlate with the disease. Infected persons can 
shed virus for weeks after recovery from clinical symptoms, and noroviruses are also 
frequently detected in stool samples from asymptomatic patients. Chan et al. analyzed data 
collected from sporadic cases and speculated a correlation between viral load and virus 
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transmission from infected persons to susceptible hosts through fecal-oral route [50]. This 
finding indicates that assessment of a possible difference in viral load in samples may be a 
useful tool to aid clinical interpretation and to assess causal relationship.
Given the rapid spread of noroviruses, especially during outbreaks, timely diagnosis is 
essential to assist management and implementation of appropriate control measures. Rapid 
commercial assays, such as enzyme immunoassays (EIAs) have been cleared by the US 
Food and Drug Administration to detect norovirus antigen in stool samples during 
outbreaks. However, due to the poor sensitivity of EIAs [51], samples with negative results 
should be confirmed by a second technique, such as RT-qPCR [52]. Consequently, EIA kits 
should not replace molecular methods during outbreak investigations, and caution should be 
used when interpreting test results from sporadic cases [52].
In the absence of laboratory diagnostic tests or delays in obtaining laboratory results, 
outbreaks of norovirus infection can be identified according to Kaplan criteria [53]. These 
criteria are based on the clinical and epidemiological profile of illness, which include (1) 
vomiting in >50% of patients, (2) a mean incubation period of 24–48 h, (3) a mean duration 
of illness of 12–60 h, and (4) lack of bacterial pathogens in stool culture. The set of Kaplan 
criteria is highly specific (99%), although with moderate sensitivity (68%) in discriminating 
outbreaks due to bacteria from those due to norovirus [54]. In LTCF, outbreaks satisfying 
Kaplan's criteria may justify rapid institution of control measures to limit spread of 
infection.
Treatment
Currently, there is no specific antiviral therapy available to treat norovirus infection. The 
management of patients is primarily supportive and focuses on treatment of dehydration and 
infection control measures to prevent further spread. Dehydration is the most common 
complication that requires medical care and is especially of concern among LTCF residents 
with underlying chronic conditions [55]. Patients with comorbidities are often prescribed 
multiple medications, some of which may have a potential for drug interactions. Therefore, 
the effect of fluid and electrolyte disturbance on medications should be closely monitored 
among elderly patients.
Despite recent progress in the development of norovirus vaccines, licensed products are not 
yet available. Clinical trials have demonstrated safety, immunogenicity, and efficacy of some 
products [56, 57], although the development of norovirus vaccines is challenging due to the 
high degree of virus genetic diversity, rapidly evolving new variant strains, and an 
incomplete understanding of immune correlates of protection [41••, 58••]. The future 
efficacy of norovirus vaccines may rely on the development of products eliciting a broad 
cross-protective immune response against heterologous virus [41••]. It is clear that older 
adults living in LTCFs are at higher risks of norovirus infection and are more likely to have 
worse outcomes. Therefore, vaccinating LTCFs residents would be beneficial to directly 
prevent infection transmission and reduce disease burden [59•].
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Prevention and Control of Norovirus Outbreaks in LTCFs
The highly infectious nature of noroviruses and their environmental persistence pose 
multiple challenges to infection management in LTCFs. In 2011, the Centers for Disease 
Control and Prevention published guidelines providing recommendations for the prevention 
and control of norovirus gastroenteritis outbreaks in healthcare facilities [60]. Table 1 
summarizes the risk-based approach for norovirus infection prevention and management in 
LTCFs, based on these guidelines and other published recommendations [52, 60, 62, 63, 
73•]. The major strategies have included measures for timely diagnosis and implementation 
of infection control interventions to limit virus transmission.
Cohorting and Exclusion
Social distancing measures, such as isolation or cohorting of symptomatic patients, have 
been successful in limiting norovirus transmission in large outbreaks [61]; however, the 
appropriate duration of isolation and use of contact precautions are uncertain. Patients may 
continue to shed norovirus in their stool after resolution of symptoms, and recommendations 
have been made to minimize contact with patients during the acute phase of illness, and 24–
72 h following recovery while patients still shed virus at high levels [52]. This is particularly 
important during outbreaks in LTCFs to help break the transmission cycle, prevent the 
amount of secondary transmission, and also decrease the outbreak duration. Most guidelines 
recommend cohorting patients into groups according to symptomatic, exposed 
asymptomatic, and unexposed asymptomatic status, with dedicated healthcare staff 
providing care for infected patients [52, 62, 63]. To minimize the risk of transmission from 
incubating or asymptomatic cases, such patients should not be transferred to unaffected 
areas, typically within 48 h after exposure [52].
Environmental Disinfection
Noroviruses are stable and persistent in the environment [64]. Current evidence suggests that 
environmental contamination with norovirus is common both within and outside outbreak 
settings [28]. Therefore, environmental cleaning and chemical disinfection are essential to 
interrupt the chain of virus transmission. To maximize penetration and efficacy, initial 
cleaning to remove gross organic matter should precede chemical disinfection. CDC 
recommends sodium hypochlorite at concentration of ≥1000 ppm for disinfection of hard 
and non-porous environmental surfaces if feasible [52, 65]. The US Environmental 
Protection Agency (EPA) has published a list of registered disinfectants for use in healthcare 
settings against noroviruses (https://www.epa.gov/sites/production/files/2016-06/documents/
list_g_norovirus.pdf).
Hand Hygiene
Hand hygiene is another key part of interrupting the norovirus transmission cycle, including 
environmentally mediated transmission as contaminated hands can transfer virus to touched 
surfaces, or vice versa [66]. Actively promoting adherence to hand hygiene among staff and 
residents is strongly recommended and should be implemented [52]. Handwashing with 
soap and water have been reported as preferred means to prevent infection, especially during 
an outbreak or if there is gross fecal soiling of the hands [8, 52]. The efficacy of alcohol-
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based sanitizers against noroviruses remains controversial, and further research is required to 
evaluate the efficacy of alcohol-based hand sanitizers against the virus [67, 68]. As an 
additional preventive strategy during outbreaks, use of gloves is recommended.
Staff Members
Staff of LTCFs plays an important role in infection transmission. A recent meta-analysis 
summarizing risk factors of norovirus spread in nursing homes found a positive association 
between bedside care and the infection [69]. Training staff on the relevant guidelines and 
personal hygiene practices is important to prevent transmission in LTCFs. Exposure to vomit 
is another infectious risk [69]. Use of personal protective equipment, including gowns and 
facial masks, is recommended for staff entering the patient care area or caring for patients 
with gastroenteritis symptoms to reduce the likelihood of exposure [60]. Ill staff members 
should not return to work until ≥48 h after symptoms resolve [52, 70]. During outbreaks of 
norovirus, staff working in multiple facilities may facilitate spread of infection to other 
LTCF.
Food Safety
While food may become contaminated during production, most norovirus contamination 
occurs during preparation [71•]. Bare-hand contact by contagious workers with ready-to-eat 
foods has been frequently identified in the majority of reported foodborne norovirus 
outbreaks [71•]. Highly infectious noroviruses may be transmitted through contaminated 
food by ill catering or food service staff in LTCFs. Therefore, food handlers are 
recommended to adherence to appropriate recommendations for hand washing and avoiding 
bare-hand contact with ready-to-eat foods (e.g., through use of gloves or utensils). Ill food 
handlers should not return to work until ≥48 h after symptom resolve [71•]. For 
asymptomatic food service staff who have tested positive for norovirus, exclusion is 
recommended [52]. CDC also recommends washing fresh product and thoroughly cooking 
shellfish as additional specific measures for preventing foodborne norovirus transmission 
(http://www.cdc.gov/norovirus/preventing-infection.html).
Surveillance and Outbreak Management
Surveillance for norovirus infection is recommended in LTCFs to determine infection rates 
and outbreaks using the standard case definition [48]. Outbreaks of norovirus infection 
should be reported to health departments in accordance with local regulations. Outbreak 
management is a multistage process, including preparedness, identification, response, and 
evaluation [72]. Guidelines for managing norovirus outbreaks have been published by public 
health agencies in several high-income countries [60, 62, 63]. Generally, LTCFs should 
develop outbreak plans outlining management arrangements for outbreaks, which may 
require involvement of public health agencies. A facility outbreak control team, including 
physicians, nurses, facility managers, and domestic staff should aim to minimize the early 
spread of infection. The main approaches to infection control and prevention include 
implementing policies concerning hand hygiene, patient isolation and cohorting, ill staff 
exclusion from work, visitor restrictions, food safety, and environmental cleaning and 
disinfection [52, 60, 62, 63, 73•]. Early detection and isolation of sporadic cases are also 
recommended to reduce the impact of noroviruses introduced into LTCFs [69].
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Conclusions
The key means of managing norovirus infection in LTCFs are well-functioning infection 
control programs. Current guidelines for prevention and control are generally based on 
infection control principles, although the efficacy of those control measures is poorly 
quantified due to the inability to culture the virus. With the recent breakthroughs of human 
norovirus in vitro culture, doors are now opened to, for example, definitively evaluate the 
efficacy of environmental disinfectants and hand hygiene options. In addition, there is no 
specific antiviral therapy available to treat norovirus infection. Therefore, development of 
licensed vaccines against noroviruses may provide another important tool for infection 
prevention among high-risk individuals.
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Fig. 1. Norovirus transmission in long-term care facilities
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Table 1
Measures recommended to manage norovirus infection in long-term care facilities
Surveillance and diagnosis
 • Surveillance for infectious gastroenteritis
 • Access to laboratory facilities capable of timely and accurate diagnosis of infection;
 • Rapid testing of stool specimens for norovirus
 • Outbreak notifications to appropriate health departments if norovirus gastroenteritis is suspected
Disease control and prevention practices
 Interruption of person-to-person transmission
   • Isolation and cohorting of infected persons, if feasible
   • Minimizing resident transfers
   • Adherence to personal protective equipment use for persons entering the patient care areas or caring for ill residents
   • Hand hygiene with soap and water after contact with infected residents, their body substances, or potentially contaminated environment
   • Informing visitors and residents about importance of hand hygiene to prevent infection spread
   • Training staff about the transmission, clinical features, diagnosis, management, and prevention of norovirus infection
   • Minimizing staff working at multiple facilities
   • Ill staff exclusion until ≥48 h after symptoms resolve
 Interruption of transmission via contaminated environment
   • Disinfection and clean areas of any organic material
   • Disinfection and sterilization using EPA approved products
   • Restriction of staff working in contaminated areas
   • Increasing the frequency of cleaning and disinfection of patient care areas and frequently touched surfaces during outbreaks
 Interruption of transmission via contaminated food and water
   • Avoiding bare-hand contact with ready-to-eat foods and appropriately hand hygiene practice before preparing foods
   • Washing fresh foods and cooking shellfish thoroughly
   • Enhancing cleaning in food facilities and contaminated areas
   • Exclusion of ill food handlers until ≥48 h after symptoms resolve
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